GenMont Biotech Inc - Asset Resilience Ratio

Latest as of March 2026: 13.40%

GenMont Biotech Inc (3164) has an Asset Resilience Ratio of 13.40% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$228.21 Million

≈ $7.19 Million USD Cash + Short-term Investments

Total Assets

NT$1.70 Billion

≈ $53.65 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2003–2025)

This chart shows how GenMont Biotech Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of GenMont Biotech Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down GenMont Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 3164 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$228.21 Million	13.4%
Total Liquid Assets	NT$228.21 Million	13.40%

Asset Resilience Insights

Moderate Liquidity: GenMont Biotech Inc has 13.40% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

GenMont Biotech Inc Industry Peers by Asset Resilience Ratio

Compare GenMont Biotech Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%

Annual Asset Resilience Ratio for GenMont Biotech Inc (2003–2025)

The table below shows the annual Asset Resilience Ratio data for GenMont Biotech Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	19.76%	NT$329.06 Million ≈ $10.37 Million	NT$1.67 Billion ≈ $52.46 Million	+5.24pp
2024-12-31	14.52%	NT$248.13 Million ≈ $7.82 Million	NT$1.71 Billion ≈ $53.83 Million	-1.97pp
2023-12-31	16.50%	NT$272.71 Million ≈ $8.59 Million	NT$1.65 Billion ≈ $52.08 Million	+0.74pp
2022-12-31	15.76%	NT$267.26 Million ≈ $8.42 Million	NT$1.70 Billion ≈ $53.43 Million	+0.93pp
2021-12-31	14.83%	NT$251.78 Million ≈ $7.93 Million	NT$1.70 Billion ≈ $53.50 Million	+3.03pp
2020-12-31	11.80%	NT$190.28 Million ≈ $5.99 Million	NT$1.61 Billion ≈ $50.81 Million	-9.51pp
2019-12-31	21.31%	NT$334.80 Million ≈ $10.55 Million	NT$1.57 Billion ≈ $49.50 Million	-21.00pp
2018-12-31	42.31%	NT$701.60 Million ≈ $22.10 Million	NT$1.66 Billion ≈ $52.25 Million	+28.86pp
2017-12-31	13.44%	NT$201.69 Million ≈ $6.35 Million	NT$1.50 Billion ≈ $47.26 Million	+4.45pp
2016-12-31	8.99%	NT$126.24 Million ≈ $3.98 Million	NT$1.40 Billion ≈ $44.23 Million	-2.69pp
2015-12-31	11.68%	NT$190.89 Million ≈ $6.01 Million	NT$1.63 Billion ≈ $51.47 Million	+12.49pp
2014-12-31	-0.81%	NT$-14.05 Million ≈ $-442.56K	NT$1.74 Billion ≈ $54.88 Million	-44.92pp
2013-12-31	44.11%	NT$606.01 Million ≈ $19.09 Million	NT$1.37 Billion ≈ $43.28 Million	-4.03pp
2012-12-31	48.15%	NT$687.66 Million ≈ $21.66 Million	NT$1.43 Billion ≈ $45.00 Million	-11.31pp
2011-12-31	59.46%	NT$887.58 Million ≈ $27.96 Million	NT$1.49 Billion ≈ $47.03 Million	+71.86pp
2010-12-31	-12.40%	NT$-169.36 Million ≈ $-5.34 Million	NT$1.37 Billion ≈ $43.02 Million	-61.81pp
2007-12-31	49.41%	NT$282.47 Million ≈ $8.90 Million	NT$571.68 Million ≈ $18.01 Million	+48.57pp
2006-12-31	0.84%	NT$4.39 Million ≈ $138.18K	NT$520.93 Million ≈ $16.41 Million	-0.48pp
2005-12-31	1.32%	NT$4.15 Million ≈ $130.87K	NT$313.55 Million ≈ $9.88 Million	-25.08pp
2004-12-31	26.41%	NT$81.62 Million ≈ $2.57 Million	NT$309.07 Million ≈ $9.74 Million	-0.65pp
2003-12-31	27.06%	NT$69.88 Million ≈ $2.20 Million	NT$258.26 Million ≈ $8.14 Million	--

pp = percentage points

About GenMont Biotech Inc

TW:3164 Taiwan Biotechnology

Market Cap

$44.71 Million

NT$1.42 Billion TWD

Market Cap Rank

#22260 Global

#1374 in Taiwan

Share Price

NT$16.50

Change (1 day)

+1.23%

52-Week Range

NT$15.90 - NT$20.30

All Time High

NT$30.54